Abstract
After relatively modest advances in the treatment of metastatic castration-resistant prostate cancer (CRPC) over the past 2 decades, the past 2 years have seen the emergence of four new agents that have improved survival for patients with advanced disease. Among these new agents are therapies that may revolutionize how prostate cancer is treated. They include an agent that targets the androgen biosynthesis pathway and a first-in-class therapeutic cancer vaccine. In addition, several new therapies are in late stages of development. As these newer agents are evaluated clinically, the rationale fir combination therapy will be evaluated based on preclinical and preliminary clinical data. The results of these continued investigations may help develop future treatment strategies for men with metastatic CRPC.
